|
|
|
|
|
|
|
|
|
01.05.26 - 08:18
|
BAE faces £120m lawsuit over decision to scrap support for aid aircraft (The Guardian)
|
|
|
EnComm Aviation says the firm's action has cut off vital support for crisis-hit countries including South Sudan and the DRCBritain's biggest weapons manufacturer, BAE Systems, is facing a £120m lawsuit after scrapping support for aircraft used to deliver aid to some of the world's neediest countries.EnComm Aviation, a Kenya-based aid cargo operator, claims the decision forced the cancellation of humanitarian contracts and reduced supplies to South Sudan, now threatened by famine, Somalia and the Democratic Republic of the Congo (DRC), among others. Continue reading......
|
|
|
01.05.26 - 08:15
|
Pearson Q1 2026 Trading Update (Unaudited) (PR Newswire)
|
|
|
Continued execution drives good Q1 result. On track to deliver 2026 guidance. Highlights Underlying Group sales up 4% in Q1. All business units performing in line with expectations; continued strong performance in Virtual Learning with underlying sales up 21%, and Assessment &......
|
|
|
|
|
|
|
|
|
|
|
01.05.26 - 08:09
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 18000 Pence belassen. Die Empfehlung eines US-Beratergremiums, das Medikament Camizestrant für eine spezielle Anwendung nicht zuzulassen, ......
|
|
|
|
|
|
|
01.05.26 - 08:06
|
FDA ODAC vote on camizestrant in breast cancer (Cision)
|
|
|
01 May 2026
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation,...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|